Observational studyBritish journal of haematology2025
Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study).
Observational study in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI).British journal of haematology · 2026Observational
- Avatrombopag in thrombopoietin receptor agonist-naïve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study.Research and practice in thrombosis and haemostasis · 2026Article
- Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.British journal of haematology · 2026Article
- Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma.JAMA network open · 2026Observational
- Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study.Blood vessels, thrombosis & hemostasis · 2026Article
- Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study).British journal of haematology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.